Glomerular cell atlas of multi-disease model revealed the characteristic changes of glomerular cell subtypes in diseases.

多疾病模型的肾小球细胞图谱揭示了疾病中肾小球细胞亚型的特征性变化。

阅读:3
Although a range of glomerular diseases profoundly affect glomerulus-associated cells, a comprehensive understanding of their molecular alterations is still lacking. Here, we performed in-depth analysis of glomerular data from mouse models of primary and secondary glomerulopathies and constructed a multi-disease cellular landscape of glomerular cells. We identified a putative subset of proliferative glomerular endothelial cells(gECs) that highly expresses genetic susceptibility genes associated with multiple glomerular diseases. Podocytes exhibited shared injury-associated cell types across different disease models. A podocyte subset highly expressing Endou, Cd200, Lgmn, Il18, Dmpk, and Spon2 was predominantly derived from ob/ob mice, whereas another podocyte subset with high expression of Selenbp1, Lpar1, S100a8, S100a9, and Sult1a1 was mainly observed in adriamycin-induced mice. Mesangial cells shared common injury-related alterations across diseases (high expression of Cxcl1, egr1, hspa1b, socs3 and dnajb1), while ob/ob mice exhibited a distinct mesangial cell subset (high expression of aldh1a2, thbs1 and fbln5). In contrast, the gECs displayed similar molecular changes across different diseases without giving rise to disease-specific subtypes. Intercellular ligand-receptor analysis underpins the recruitment of immune cells by injured mesangial cells and podocytes via specific engagement of pairs such as CXCL and MIF, respectively. Our study systematically elucidates the molecular alterations of glomerulus-associated cells across various diseases, providing a foundation and strategic insights for future targeted therapies tailored to specific glomerular disease contexts.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。